The frequency of SRSF2 mutation in AML patients is approximately 10%, whereas in myelodysplastic syndrome (MDS) patients it ranges from 20% to 30%, and it is approximately 50% in patients with CMML [11,62,64]. This evidence concerns the gene SRSF2 and chronic myelomonocytic leukemia.